1.10
-0.02(-1.79%)
Currency In USD
| Previous Close | 1.12 |
| Open | 1.1 |
| Day High | 1.13 |
| Day Low | 1.07 |
| 52-Week High | 2.43 |
| 52-Week Low | 0.61 |
| Volume | 73,262 |
| Average Volume | 933,761 |
| Market Cap | 9.76M |
| PE | 0.96 |
| EPS | 1.15 |
| Moving Average 50 Days | 1.04 |
| Moving Average 200 Days | 1.1 |
| Change | -0.02 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $12.47 as of February 05, 2025 at a share price of $1.1. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $12.42 as of February 05, 2025 at a share price of $1.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
GlobeNewswire Inc.
Jan 08, 2025 2:50 PM GMT
Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically significant results for all primary and secondary e
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
GlobeNewswire Inc.
Dec 23, 2024 2:30 PM GMT
Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note
GlobeNewswire Inc.
Nov 22, 2024 2:10 PM GMT
WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the